Download PDF
Thromb Haemost 1983; 50(04): 893
DOI: 10.1055/s-0038-1665337
Letter to the Editor
Schattauer GmbH Stuttgart

Fibrinolytic Activity of 6-Keto-Prostaglandin E1

R Korbut
The Institute of Pharmacology, N. Copernicus Academy of Medicine, 31-531 Kraków, Poland
,
A Byrska-Danek
The Institute of Pharmacology, N. Copernicus Academy of Medicine, 31-531 Kraków, Poland
,
R J Gryglewski
The Institute of Pharmacology, N. Copernicus Academy of Medicine, 31-531 Kraków, Poland
› Author Affiliations
Further Information

Publication History

Received 08 June 1983

Accepted 18 August 1983

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Utsunomiya T, Krausz MM, Valeri CR, Shepro D, Hechtman HB. Treatment of pulmonary embolism with prostacyclin. Surgery 1980; 88: 25-30
    PubMedGoogle Scholar
  • 2 Dembińska-Kieć A, Kostka-Trabka E, Gryglewski RJ. Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans. Thromb Haemostas 1982; 47: 190
    PubMedGoogle Scholar
  • 3 Wong PY-K, Malik KU, Desiderio DM, McGiff JC, Sun FF. Hepatic metabolism of prostacyclin (PGI2) in the rabbit: Formation of a potent novel inhibitor of platelet aggregation. Biochem Biophys Res Comm 1980; 93: 486-494
    CrossrefPubMedGoogle Scholar
  • 4 Kaulla vonK, Schultz RL. Methods for evaluation of human fibrinolysis: Studies with two combined techniques. Am J Clin Pathol 1958; 29: 104-112
    CrossrefPubMedGoogle Scholar
  • 5 Skuballa W, Vorbrüggen H. Synthesis of Ciloprost (ZK 36374): A chemically stable and biologically potent prostacyclin analog. Advances in Prostaglandin, Thromboxane and Leukotriene Research. Samuelsson B, Paoletti R, Ramwell P. (Eds) Raven Press; New York: 1983. 11 299-305
    Google Scholar